Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dorzolamide Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Dorzolamide Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bepotastine
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2021
Lead Product(s) : Bepotastine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difluprednate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Difluprednate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable